Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Clinical features modifying the cardiovascular benefits of GLP-1 receptor agonists: a systematic review and meta-analysis

Open access
Kalayci, Arzu, Januzzi, James Louis, Mitsunami, Makiko, Tanboga, Ibrahim Halil, Karabay, Can Yucel, Gibson, Charles Michael · 2025 · European Heart Journal - Cardiovascular Pharmacotherapy

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D), but heterogeneity exists across cardiovascular outcome trials (CVOTs). A comprehensive search of PubMed, EMBASE, and Cochrane Library was conducted through November 2024. Eligible CVOTs compared GLP-1 RAs with placebo in T2D patients. The primary outcome was MACE, defined as a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using a random-effects model. Heterogeneity was assessed using I², τ², and R². Meta-regression analyses evaluated the influence of baseline covariates on cardiovascular benefits of GLP-1 RAs, contingent upon the detection of moderate to substantial heterogeneity (I² ≥ 30%). Sensitivity analyses and GRADE assessments were also performed. Ten trials (67 769 patients; 34 536 receiving GLP-1 RAs) were analyzed. GLP-1 RAs significantly reduced MACE compared with placebo (OR = 0.87, 95% CI: 0.81–0.93, P < 0.001, I² = 48.4%). Cardiovascular death (OR = 0.86, 95% CI: 0.79–0.94, P < 0.001, I² = 22.6%) and all-cause mortality (OR = 0.87, 95% CI: 0.82–0.94, P < 0.001, I² = 17.7%) were also reduced. Meta-regression revealed a greater cardiovascular benefit in patients with higher baseline body mass index (BMI; logOR = −0.098 per kg/m², P = 0.006, R² = 99.98%) and older age (logOR = −0.033 per year, P = 0.023, R² = 75.47%). Sensitivity analyses confirmed the robustness of these findings, with consistent effect sizes and no single trial unduly influencing the results. The certainty of evidence was rated as high for all outcomes based on GRADE criteria. GLP-1 RAs significantly reduce MACE, cardiovascular death, and all-cause mortality in T2D patients. Higher baseline BMI and older age were associated with greater cardiovascular benefit.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ehjcvp/pvaf037

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical Abstract
Graphical Abstract CC BY · PubMed Central
Fig. 1. (A). Major adverse cardiovascular events.
Fig. 1. (A). Major adverse cardiovascular events.CC BY · PubMed Central
Fig. 2. (B). Cardiovascular death.
Fig. 2. (B). Cardiovascular death.CC BY · PubMed Central
Fig. 3. (C). All-cause death.
Fig. 3. (C). All-cause death.CC BY · PubMed Central
Fig. 4. Meta-regression of the treatment effect of GLP-1 RAs on MACE by baseline BMI.
Fig. 4. Meta-regression of the treatment effect of GLP-1 RAs on MACE by baseline BMI.CC BY · PubMed Central
Fig. 5. Meta-regression of the treatment effect of GLP-1 RAs on MACE by age.
Fig. 5. Meta-regression of the treatment effect of GLP-1 RAs on MACE by age.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Research works printed but not linked: 1

  1. International Diabetes Federation, 2025, IDF Diabetes Atlas

Cited by

See all 24

Metadata

Authors
Kalayci, A., Januzzi, J. L., Mitsunami, M., Tanboga, I. H., Karabay, C. Y., & Gibson, C. M.
Affiliations
  • Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School , 75 Francis Street, Boston, MA 02115 ,
  • Harvard University (US)
  • Department of Cardiology, Hisar Intercontinental Hospital, Nişantaşı University , Yamanevler, Site Yolu Cd No:7, 34768 Umraniye, Istanbul ,
  • Department of Cardiology, Dr. Siyami Ersek Training and Research Hospital, University of Health Sciences , Selimiye, Tibbiye Cd No:25, 34668 Uskudar, Istanbul ,
  • Beth Israel Deaconess Medical Center (US)
Corresponding author
Gibson, Charles Michael
Venue
European Heart Journal - Cardiovascular Pharmacotherapy
Published
2025-08-31
Volume
11
Issue
6
Pages
552-561
ISSN
  • 2055-6837 (ISSN-L)
  • 2055-6845
OpenAlex
W4413882572
Cited by
18
References
36
Citations by year
2026: 16 · 2025: 2
FWCI
2.45
Type
journal article
Language
en
Open access
Locations
  • European Heart Journal - Cardiovascular Pharmacotherapy (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
Funders
National Heart, Lung, and Blood Institute (T32HL094301)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
GLP-1 receptor agonists, type 2 diabetes, major adverse cardiovascular events, cardiovascular outcome trials, cardiovascular mortality, body mass index, age, baseline covariates, cardiovascular risk factors, weight loss, myocardial infarction, stroke, all-cause mortality, sex differences, alcohol consumption, physical activity
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Risk Factors, Randomized Controlled Trials as Topic, Treatment Outcome, Risk Assessment, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical features modifying the cardiovascular benefits of GLP-1 receptor agonists: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1093/ehjcvp/pvaf037
The paper
Kalayci, A., Januzzi, J. L., Mitsunami, M., Tanboga, I. H., Karabay, C. Y., & Gibson, C. M. (2025). Clinical features modifying the cardiovascular benefits of GLP-1 receptor agonists: a systematic review and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvaf037

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.